HDAC9 and cancer: The perturbational class identified in our study, namely PI3K inhibitors [49], mTOR inhibitors [50], IGF-1 inhibitors [51], JAK inhibitors [52], DNA dependent protein kinase inhibitors [53], HDAC inhibitors [54], and FLT3 inhibitors [55], were also reported to mediate immune modulation in various cancers.